摘要
哺乳动物细胞的有氧代谢引起了新一代活性氧(ROS)的产生。为了应付这种毒副作用,演变过程中提供了有效抗氧化系统如谷胱甘肽。目前的癌症治疗主要集中于肿瘤依赖的致癌基因和非癌基因。为了避免肿瘤胁迫和细胞凋亡的肿瘤触发机制。关于此我们已经研究了2-phenylethinesulfoxamine (PES),其可以禁用细胞保护机制来面临受损及未折叠蛋白的毒性。肿瘤细胞中的蛋白毒性压力是增加的,因此为PES作为抗癌剂的选择提供了解释。此外,我们发现PES可以诱导严重的氧化应激和p53的激活。借助于丁硫氨酸(BSO)可减少谷胱甘肽细胞内容物,且与PES有协同增效作用。总之,我们已经发现ROS构成了细胞的一系列正反馈回路的核心因素。ROS、p53、蛋白质毒性、自我吞噬和线粒体动态变化与导致细胞凋亡或坏死的细胞死亡机制相互连接。这种相互作用的网络为癌症药物的发现与开发提供多靶点。
关键词: 细胞死亡,细胞实验药理,丁硫氨酸,Mdivi-1,氧化应激,p53
Current Drug Targets
Title:Pharmacological Modulation of Reactive Oxygen Species in Cancer Treatment
Volume: 16 Issue: 1
Author(s): Judit Ribas, Paolo Mattiolo and Jacint Boix
Affiliation:
关键词: 细胞死亡,细胞实验药理,丁硫氨酸,Mdivi-1,氧化应激,p53
摘要: Aerobic metabolism of mammalian cells leads to the generation of reactive oxygen species (ROS). To cope with this toxicity, evolution provided cells with effective antioxidant systems like glutathione. Current anticancer therapies focus on the cancer dependence on oncogenes and non-oncogenes. Tumors trigger mechanisms to circumvent the oncogenic stress and to escape cell death. In this context we have studied 2-phenylethinesulfoxamine (PES), which disables the cell protective mechanisms to confront the proteotoxicity of damaged and unfolded proteins. Proteotoxic stress is increased in tumor cells, thus providing an explanation for the anticancer selectivity of PES. In addition, we have found that PES induces a severe oxidative stress and the activation of p53. The reduction of the cell content in glutathione by means of L-buthionine-sulfoximine (BSO) synergizes with PES. In conclusion, we have found that ROS constitutes a central element in a series of positive feed-back loops in the cell. ROS, p53, proteotoxicity, autophagy and mitochondrial dynamics are interconnected with the mechanisms leading to cell death, either apoptotic or necrotic. This network of interactions provides multiple targets for drug discovery and development in cancer.
Export Options
About this article
Cite this article as:
Judit Ribas, Paolo Mattiolo and Jacint Boix , Pharmacological Modulation of Reactive Oxygen Species in Cancer Treatment, Current Drug Targets 2015; 16 (1) . https://dx.doi.org/10.2174/1389450115666141114153536
DOI https://dx.doi.org/10.2174/1389450115666141114153536 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroprotective Properties of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) and its Lipid Ligands
Current Medicinal Chemistry Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches
Current Molecular Pharmacology Editorial [Hot topic: Targeting Nitric Oxide for Tumor Therapy (Executive Editor: Antonio Contestabile)]
Current Pharmaceutical Design Anabolic Androgenic Steroids and Intracellular Calcium Signaling: A Mini Review on Mechanisms and Physiological Implications
Mini-Reviews in Medicinal Chemistry Withaferin A Regulates LRRK2 Levels by Interfering with the Hsp90- Cdc37 Chaperone Complex
Current Aging Science P-Glycoprotein, but not Multidrug Resistance Protein 4, Plays a Role in the Systemic Clearance of Irinotecan and SN-38 in Mice
Drug Metabolism Letters <i>Rhizoma Coptidis</i> for Alzheimer’s Disease and Vascular Dementia: A Literature Review
Current Vascular Pharmacology Xanthones from Mangosteen Extracts as Natural Chemopreventive Agents: Potential Anticancer Drugs
Current Molecular Medicine Pulmonary Circulation and Pulmonary Function in Neonatal Lung Hypoplasia:Treatment with Corticosteroids
Current Pediatric Reviews Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen
Current Pharmaceutical Design JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms
Current Medicinal Chemistry Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Proteomic Analysis of Glioma Chemoresistance
Current Neuropharmacology Recent Patents in Cationic Lipid Carriers for Delivery of Nucleic Acids
Recent Patents on DNA & Gene Sequences Cholesterol Oxidation Products and Disease: An Emerging Topic of Interest in Medicinal Chemistry
Current Medicinal Chemistry The Role of Oxidative Stress and Anti-Oxidant Treatment in Platinum- Induced Peripheral Neurotoxicity
Current Cancer Drug Targets An Insight into the Therapeutic Potential of Major Coffee Components
Current Drug Metabolism Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections
Current Topics in Medicinal Chemistry Neurotoxicity of β-Amyloid Protein: Oligomerization, Channel Formation and Calcium Dyshomeostasis
Current Pharmaceutical Design Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets